Articles tagged with Vaccine Development
A new intranasal vaccine against pertussis has been successfully tested in humans, inducing an immune response that lasted for at least 6 months. The vaccine was found to be safe and effective, with no adverse events reported even at the high dose.
A study published in Neurology suggests that a vaccine used to prevent tuberculosis may help prevent multiple sclerosis in people showing early signs of the disease. After six months, vaccinated individuals had fewer brain lesions than those who received a placebo, with 58% not developing MS compared to 30%.
A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, by wrapping it in a polymer chain. This discovery could lead to the development of stable vaccines and affordable artificial blood substitutes.
A new rabies vaccine aims to develop a single dose contraceptive vaccine, reducing child deaths and controlling dog rabies. The vaccine targets dendritic cells to induce strong immune responses against rabies and foreign antigens.
Researchers identified a genetic signature for respiratory syncytial virus (RSV), which causes severe pneumonia and bronchiolitis in infants. The discovery will help develop a vaccine and improve disease severity prediction using RNA profiles.
The updated 2013 Malaria Vaccine Technology Roadmap sets a new target for vaccines to reduce malaria cases by 75 percent and be licensed by 2030. The roadmap also aims for malaria elimination through the development of safe and effective vaccines that prevent disease, death, and transmission.
Professor Alan Cowman has been recognized for his substantial contributions to understanding malaria development and drug resistance. His work has led to the development of two potential malaria vaccines, one in clinical trials and the other in preclinical development.
A three-year project aims to create an oral vaccine against C. difficile, which kills thousands annually. The novel approach uses harmless bacterial spores to boost immunity and targets the protein needed for the infection to take hold.
Researchers say Chagas disease remains a leading cause of heart disease in impoverished North American communities, with inadequate healthcare and limited treatment options available. The editorial calls for increased medical awareness, scientific cooperation, and public-private partnerships to develop new tools and treatments.
Scientists at Arizona State University have developed a microchip-based technology called immunosignature diagnosis that can rapidly measure an individual's vaccine response. This innovation has the potential to significantly reduce the costs and timeframes of vaccine testing, allowing for more effective vaccines to be identified.
A clinical study published in The Lancet Infectious Diseases shows that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. This breakthrough finding has significant implications for vaccination strategies and cost-effectiveness in developing countries.
Professor Alan Cowman's work has led to a better understanding of malaria biology, informing new treatments and vaccines. The development of potential malaria vaccines is a significant step towards eradicating the disease.
A new research project will develop the next generation of effective mucosal vaccines using immunomodulation and cell-targeted nanoparticles. This innovation aims to improve vaccine administration in resource-poor settings, reducing blood-borne contamination and pandemic spread risks.
Researchers have developed a new tuberculosis vaccine that acts as a booster to the existing Bacille Calmette Guerin (BCG) vaccine, which is ineffective in many cases. The vaccine was tested in a phase one clinical study and showed a robust immune response in most trial participants.
Firdausi Qadri, a renowned Bangladeshi immunologist, has been awarded the prestigious C.N.R. Rao Prize for her groundbreaking research on enteric diseases and innovative mass immunization strategies. Her work aims to develop new approaches to combat common infectious diseases in developing countries.
A new consortium led by the Sabin Vaccine Institute is conducting clinical trials of a human hookworm vaccine in Gabon. The vaccine has the potential to dramatically improve health, economic, and social landscapes in countries with high burdens of hookworm disease.
Duke Medicine has been named a Vaccine and Treatment Evaluation Unit (VTEU) to evaluate vaccines, treatments, and diagnostics. The VTEU will focus on vaccine development for diseases other than HIV, with potential annual funding of up to $135 million.
The National Institutes of Health has awarded a nearly $1 billion contract to Saint Louis University's Center for Vaccine Development, recognizing the institution's leadership role in vaccine research. The seven-year contract will support clinical trials and lab studies for new vaccines, with a focus on emerging threats.
The National Institute of Allergy and Infectious Diseases has renewed a 10-year contract with the University of Maryland School of Medicine's Center for Vaccine Development, providing up to $135 million in annual funding. The center will conduct basic research, clinical studies, and vaccine development to combat existing and emerging i...
Researchers at Scripps Research Institute discovered that an antibody binding to HIV likely targets the body's own proteins, complicating its development as a vaccine. The finding raises concerns about potential autoimmune diseases and self-reactivity in 4E10 antibodies.
A novel vaccine approach against human cytomegalovirus (CMV) has been shown to be safe and more effective than previous vaccines in an animal model. The vaccine targets CMV's ability to hijack the immune system, inducing broader immunological protection.
Researchers developed a microneedle patch that delivered an effective and long-lasting influenza vaccine, providing 100% protection in mice over one year. The vaccine used virus-like particles coated on needles, reducing refrigeration needs and potential side effects.
Researchers developed a strain of rice that produces a rotavirus-specific antibody, protecting both normal and immune-deficient mice. The engineered rice maintains its efficacy even after long-term storage and heat exposure.
Researchers found that higher dosages of the PfSPZ Vaccine generated more antibodies and T cells, providing protection against malaria infection. The study's results suggest a potential breakthrough in developing a safe and effective malaria vaccine.
A new modular vaccine design called MAPS technology may generate vaccines conferring strong immunity at reduced cost and risk. The method allows for rapid construction of new vaccines that activate multiple arms of the immune system simultaneously against one or more pathogens, reducing the risk of adverse effects.
IDRI's VL vaccine candidate has shown safety and immunogenicity in healthy volunteers, and Zydus' expertise will be crucial in getting the vaccine to those who need it most. The partnership aims to make the vaccine affordable and accessible to all people in need, particularly in endemic countries.
Researchers have developed a vaccine that provides at least 60 percent protection against rotavirus in newborns, significantly reducing severe dehydration and hospitalizations. The study, published in the Journal of Infectious Diseases, suggests that early administration of the vaccine could save thousands of lives annually.
Research reveals higher diversity in gut microbiota enables more robust immune responses to vaccines. Scientists found that diverse gut bacteria may help humans resist enteric pathogens like Salmonella and Shigella.
Scientists at Emory Vaccine Center found that IL-21 is necessary for long-lasting antibody responses in mice against viral infections. The molecule stimulates germinal centers and supports T helper cells, leading to the generation of virus-specific long-lived plasma cells.
The India-developed rotavirus vaccine ROTAVAC has demonstrated excellent safety and efficacy in a Phase III clinical trial, reducing severe rotavirus diarrhoea by over half. The vaccine's impact extends beyond rotavirus infections, also showing protection against severe diarrhoea of any cause.
A new international study has pinpointed the main causes of childhood diarrheal diseases, identifying rotavirus as the leading cause among infants. The Global Enteric Multicenter Study found that targeting just four pathogens could prevent most cases and save hundreds of thousands of lives through vaccines and treatments.
The Bill & Melinda Gates Foundation has awarded a $2.9 million grant to Aeras, Oxford University, and Okairos to develop novel vaccines against tuberculosis, HIV, and malaria. The collaboration aims to create scalable methods for large-scale production of multiple chimpanzee adenovirus vector constructs.
Scientists have made a breakthrough in understanding Respiratory Syncytial Virus (RSV) by identifying a highly vulnerable site on the virus's protein. The discovery provides new insights into how neutralizing antibodies work, which could lead to the development of more effective vaccines for infant respiratory illnesses.
IDRI and Medicago present data on their H5N1 Avian Influenza VLP vaccine candidate, combining IDRI's GLA adjuvant with Medicago's proprietary manufacturing technology. The trial shows promising results in evaluating the safety and immunogenicity of the vaccine.
Researchers at MIT have developed a novel approach to protecting against the dengue virus using mutated antibodies. The new therapy has shown significant promise in neutralizing all four serotypes of the virus and could be ready for human trials within two to three years.
A study has identified a broadly cross-reactive neutralizing antibody in an infected HIV-1 patient, providing insights into effective vaccination strategies. The researchers hope that a vaccine mimicking the development of this potent antibody response may trigger similar protective antibodies.
Tracking an early immune response, researchers chart a new route for developing a long-sought HIV vaccine that boosts the body's ability to neutralize the virus. The study reveals the co-evolution of antibodies and virus in a person whose immune system mounted a broad attack against the pathogen.
Researchers at the University of Texas Medical Branch have developed a safe and simple Chagas disease vaccine candidate, TcVac3, which shows over 90 percent protection against chronic infection in mice. The potential vaccine could be approved in as few as five years for use in canines, who are reservoir hosts of the disease.
Researchers discovered a way to re-activate the immune system to fight parasitic worms, potentially leading to vaccines for diseases like elephantiasis and river blindness. This breakthrough could also inform treatments for allergies.
A team of researchers from La Jolla Institute and Cardiff University has identified a novel cellular mechanism that could aid in creating a CMV vaccine. The study found that a specific CMV protein blocks the ability of immune pathways to kill infected cells, providing an important piece of the CMV puzzle.
A Phase I clinical trial of a tetravalent candidate dengue vaccine found it induced a balanced antibody response against all four dengue viruses in most recipients. The vaccine was safe, and its development is promising for preventing severe dengue disease.
The Johns Hopkins Bloomberg School will provide relief agencies and governments with technical assistance on using oral cholera vaccine. The DOVE program aims to detect outbreaks in remote areas and contain the disease, improving global efforts to combat cholera.
Researchers will study how maternal parasite infections affect fetal immune systems to identify effective interventions promoting healthy growth in children. The goal is to understand the causes of stunted growth and develop affordable solutions.
The MenAfriVac meningitis A vaccine has been approved for use outside the cold chain for up to four days, enabling expanded access to vaccination programs. The vaccine's heat stability has been validated through a rigorous review and pilot use in Benin, with promising results showing reduced disease burden and herd immunity.
A new equine vaccine, Equivac HeV, has been developed to prevent clinical disease caused by Hendra virus in horses. The vaccine, derived from the original work of Christopher C. Broder and Katharine Bossart, is now available for use in Australia.
Benaroya Research Institute (BRI) has received a $100,000 grant from the Bill & Melinda Gates Foundation to develop rapid malaria vaccines using synthetic minigene libraries. This innovative approach aims to identify protective target antigens in a fraction of the time required by conventional technologies.
Researchers at Columbia University Irving Medical Center have developed a groundbreaking mouse model of typhoid fever, enabling the study and creation of more effective vaccines. The mouse model uses toll-like receptors to combat the infection, with promising results in immunizing mice against Salmonella typhi.
Researchers have developed a mouse model of typhoid fever, allowing for more effective vaccine development against the deadly pathogen. The model shows human-like symptoms and responds positively to immunization.
A team of Cardiff University scientists is working on a NATO project to develop an effective anthrax vaccine against the threat of bioterrorism. The goal is to protect civilians and workers at risk from infection with Bacillus anthracis.
Sanofi Pasteur's CYD-TDV vaccine candidate has shown promise in a phase IIb clinical trial, with effectiveness against DENV 1, 3 and 4 but not DENV 2. The results mark a significant step forward in dengue vaccine development.
A new dengue vaccine candidate, CYD-TDV, has shown promising results in a phase 2b trial with an effective rate of 60-90% against DENV 1, 3, and 4 viruses. The vaccine was also found to be safe and well-tolerated, with no serious adverse events reported.
A recent Special Focus in Human Vaccines & Immunotherapeutics discusses the mistakes of past cancer vaccine programs and provides critical insights into the future of cancer vaccines. The study emphasizes the importance of antigen discovery and personalized approaches to overcome the challenges of tumor heterogeneity.
Dartmouth medical research has made a breakthrough in developing a new tuberculosis vaccine, DAR-901. The vaccine, produced by growing bacteria related to TB on agar plates and then inactivating them with heat, has shown a statistically significant reduction of 39% in the rate of tuberculosis among HIV-infected patients.
Lawrence Corey, a renowned expert in virology and immunology, has been honored with the Cubist-ICAAC Award for his pioneering work on herpes viruses, HIV, and cancer. His research has led to significant advances in antiviral therapy and vaccine development.
Researchers have developed a vaccine that protects African green monkeys from Nipah virus, with all nine vaccinated animals surviving a lethal challenge. The vaccine is based on a Hendra virus surface protein and is in commercial development for use in horses.
Researchers successfully developed a highly effective vaccine against the deadly Nipah virus, which has shown complete protection in African green monkeys with no evidence of disease. The vaccine, known as Hendra-sG, is a recombinant piece of the virus produced in the laboratory and can be used safely for human treatment.
Researchers at Arizona State University develop first vaccine complex that can be delivered safely and effectively by piggybacking onto self-assembled, three-dimensional DNA nanostructures. The vaccine complexes trigger a robust immune response up to 9-fold higher than traditional methods.
The new FMD vaccine is a molecular vaccine that does not use live FMD virus, allowing for differentiation between vaccinated and infected animals. This breakthrough could significantly reduce the economic impact of FMD outbreaks in the US, with potential cost savings estimated to exceed $50 billion.
A new study published in Vaccine indicates that the cost of producing a tetravalent dengue vaccine could be as low as $0.20 per dose with an annual production level of 60 million doses. This finding provides confidence to ministries of health to plan for the inclusion of dengue vaccine in their immunization programs.
Researchers have identified a master regulator gene, Spi-B, essential for the development of M cells, which play a crucial role in initiating immune responses. This discovery could aid research on oral vaccines and inflammatory bowel diseases by providing valuable insights into M cell differentiation and function.